Suomen Terveystalo Oy
- Address
- Humalistonkatu 9 11, 20100 Turku, Finland
Cardiovascular Diseases
At Suomen Terveystalo Oy in Turku, clinical trials in cardiovascular diseases focus on major conditions such as atherosclerotic cardiovascular disease, heart failure, and hypertension. These studies are designed to test new treatment options and help reduce the risk of serious events like heart attack, stroke, and cardiovascular death.
- Preventing major cardiovascular events in people with established or high-risk disease
- Studying therapies for heart failure with preserved or mildly reduced ejection fraction
- Evaluating treatments for type 2 diabetes combined with cardiovascular risk
- Assessing therapies targeting elevated lipoprotein(a) and lipid-related risk
This area reflects a strong emphasis on improving long-term outcomes for patients with complex cardiometabolic disease.
Neurology and Mental Health
Research in nervous system diseases and psychiatry includes studies on migraine, chronic migraine, insomnia disorder, and generalized anxiety disorder. These trials aim to improve symptom control, support prevention, and evaluate how well new therapies work for people whose current treatment options have been limited.
- Testing treatments for migraine attacks and migraine prevention
- Evaluating care for chronic migraine in adolescents and adults
- Studying therapies for insomnia disorder
- Assessing treatment options for generalized anxiety disorder
The research portfolio at Terveystalo Turku shows a clear interest in conditions that can strongly affect daily functioning and quality of life.
Respiratory and Allergy Research
Trials in respiratory tract diseases and immune system diseases address chronic obstructive pulmonary disease and birch pollen-induced allergic rhinoconjunctivitis. The main purpose is to explore better ways to control symptoms, reduce flare-ups, and improve breathing and comfort for patients with chronic or seasonal disease.
- Evaluating new approaches for COPD symptom control and exacerbation reduction
- Studying treatment options for allergic rhinoconjunctivitis caused by birch pollen
- Looking at ways to improve respiratory outcomes in people with ongoing lung disease
- Testing therapies that may reduce reliance on rescue medication and standard care
These studies combine allergy and lung health research with a practical focus on everyday symptom relief.
Digestive and Metabolic Disorders
The site also supports trials in digestive system diseases and nutritional and metabolic diseases, including celiac disease and type 2 diabetes. This research is aimed at improving disease control, easing persistent symptoms, and examining new treatment strategies for people managing long-term metabolic or gastrointestinal conditions.
- Assessing therapies for persistent symptoms in celiac disease
- Studying treatment approaches for type 2 diabetes linked with cardiovascular risk
- Exploring ways to improve overall disease management in chronic metabolic illness
- Evaluating options that may help patients despite standard dietary or medical care
This area highlights research that connects digestive health with broader metabolic wellbeing.
Viral Prevention and Immunization
Trials in virus diseases at the Suomen Terveystalo Oy site include work related to influenza immunisation. The goal is to evaluate vaccine performance and support better protection against seasonal infection, especially in older adults.
- Assessing immune response to influenza vaccines
- Supporting prevention of seasonal viral illness in older populations
- Studying vaccination as a public health tool for reducing infection burden
- Comparing how well different immunization approaches protect against flu
This research reflects a preventive medicine focus within the site’s broader clinical trial activity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 91 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1AstraZeneca AB2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.4trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Suomen Terveystalo Oy
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Azetukalner in Patients with Moderate-to-Severe Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 91 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 2 | Unknown | 2026-02-26 | 2026-06-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.